RemeGen CoREGMF -6.23%41 Market Cap is $9,233.5 Mil as of Jul. 02, 2026. GuruFocus rates REGMF with a GF Score™ of 41/100 and a GF Value™ of $28.05 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 1,427 Biotechnology companies, RemeGen Co ranks better than 96.92% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). RemeGen Co's share price for the quarter that ended in Dec. 2025 was $9.81. RemeGen Co's Shares Outstanding (EOP) for the quarter that ended in Dec. 2025 was 563.7 Mil. Therefore, RemeGen Co's market cap for the quarter that ended in Dec. 2025 was $5,530.0 Mil.
RemeGen Co's quarterly market cap
stayed the same
from Jun. 2025 ($2,851.9 Mil) to Sep. 2025 ($2,851.9 Mil) but then
increased
from Sep. 2025 ($2,851.9 Mil) to Dec. 2025 ($5,530.0 Mil).
RemeGen Co's annual market cap
declined
from Dec. 2023 ($2,231.5 Mil) to Dec. 2024 ($816.5 Mil) but then
increased
from Dec. 2024 ($816.5 Mil) to Dec. 2025 ($5,530.0 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. RemeGen Co's Enterprise Value for Today is $9,208.7 Mil.
RemeGen Co (OTCPK:REGMF) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
RemeGen Co Market Cap Related Terms
RemeGen Co Market Cap Historical Data
* Premium members only.
The historical data trend for RemeGen Co's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, RemeGen Co's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
RemeGen Co Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, RemeGen Co's Market Cap distribution charts can be found below:
* The bar in red indicates where RemeGen Co's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
RemeGen Co's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RemeGen Co (REGMF) has a Market Cap of $9,233.5 Mil as of Jul. 02, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on RemeGen Co and its competitors. According to the industry distribution chart, RemeGen Co ranks #44 out of 1427 companies in the Biotechnology industry, placing it in the top 3.1%.
Is RemeGen Co's Market Cap too high?
RemeGen Co's current Market Cap is $9,233.5 Mil. The Biotechnology industry median Market Cap is 119.04. RemeGen Co's value of $9,233.5 Mil is 7656.8% above this industry median. Based on the distribution chart, RemeGen Co ranks #44 out of 1427 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, RemeGen Co has a GF Score™ of 41/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does RemeGen Co's Market Cap compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, RemeGen Co ranks #44 out of 1427 companies for Market Cap. This places RemeGen Co in the top 3% of its industry — outperforming the majority of peers. The industry median Market Cap is 119.04. RemeGen Co's value of $9,233.5 Mil is 7656.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 119.04, based on 1,427 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. RemeGen Co's current Market Cap of $9,233.5 Mil is 7656.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on RemeGen Co and its competitors. For the Biotechnology industry, the median Market Cap is 119.04 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. RemeGen Co's current Market Cap is $9,233.5 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RemeGen Co stock overvalued right now?
Based on GuruFocus' analysis, RemeGen Co (REGMF) is currently considered Possible Value Trap. The stock's GF Value™ is $28.05, compared to a current price of $12.05 — trading 57% below its estimated fair value. The current Market Cap is $9,233.5 Mil and 7656.8% above the Biotechnology industry median of 119.04. RemeGen Co's overall GF Score™ is 41/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For RemeGen Co (REGMF), the current Market Cap is $9,233.5 Mil as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is RemeGen Co (REGMF) Overvalued in 2026?
Based on GuruFocus' analysis, RemeGen Co stock appears to be undervalued.
The current stock price of $12.05 is trading 57% below its estimated GF Value™ of $28.05.
GuruFocus considers RemeGen Co to be Possible Value Trap.
Key valuation signals for REGMF:
Market Cap: $9,233.5 Mil
GF Value™: $28.05 vs. price of $12.05 (57% below fair value)
Industry Position: 7656.8% above the Biotechnology median (#44 of 1427)
No single metric tells the full story. See the REGMF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
RemeGen Co Ltd is a China-based company mainly engaged in the research, development and manufacture of biopharmaceuticals. The company offers Telitacicept (RC18) for use in the treatment of systemic lupus erythematosus an autoimmune disease and Disitamab Vedotin (RC48) for use in the treatment of various cancers. The company's products are mainly used to treat severe diseases such as autoimmune diseases, oncology, and ophthalmology. It has its operations in China and the USA and derives the majority of its revenue from China.
41GF Score
Get the complete analysis for REGMF
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
REGMF has been successfully added to your 
